NCT00699842 · Interventional trial
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Overall registry status Terminated
Phase 1 · Phase 2
Conditions Low to Intermediate-1 MDS, MDS, Myelodysplastic Syndrome, Non-deletion 5q
Delaware Valley sites
- Associates in Hematology-Oncology, PC · Chester, PA · Philadelphia County
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory